{{Rsnum
|rsid=602618
|Chromosome=10
|position=112843085
|Orientation=plus
|GMAF=0.4867
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 51.3 | 45.1 | 3.5
| HCB | 11.7 | 46.7 | 41.6
| JPT | 5.3 | 42.5 | 52.2
| YRI | 8.8 | 40.1 | 51.0
| ASW | 12.3 | 54.4 | 33.3
| CHB | 11.7 | 46.7 | 41.6
| CHD | 11.0 | 45.9 | 43.1
| GIH | 26.7 | 46.5 | 26.7
| LWK | 6.4 | 37.3 | 56.4
| MEX | 44.8 | 43.1 | 12.1
| MKK | 13.5 | 36.5 | 50.0
| TSI | 49.0 | 47.1 | 3.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs602618
|Name_s=
|Gene_s=ADRA2A
|Feature=
|Evidence=PubMed ID:19965390
|Annotation=Risk or phenotype-associated allele: A allele. Phenotype: Decreased fasting insulin. Study size: 4681. Study population/ethnicity: Replication study of Swedish control subjects. Significance metric(s): p = 0.001. Type of association: FA; GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165291597
}}
{{PMID Auto
|PMID=21070505
|Title=Multiple polymorphisms in genes of the adrenergic stress system confer vulnerability to alcohol abuse
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs602618
|overall_frequency_n=64
|overall_frequency_d=128
|overall_frequency=0.5
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=61
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24166412
|Title=Alpha-2A adrenergic receptor gene variants are associated with increased intra-individual variability in response time
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}